Prothena will explore potential business development opportunities for NEOD001
Prothena reports results from post hoc analyses revealed a potential survival benefit with NEOD001 in the category of patients at the highest risk for early mortality. The company will be exploring potential business development opportunities to advance NEOD001. "We are grateful to patients, their families, investigators and study site staff who made this study, and what we have learned, possible," said Gene Kinney, Ph.D., President and Chief Executive Officer of Prothena. "Following discontinuation of the VITAL study, we analyzed the results in order to contribute to the body of knowledge about AL amyloidosis with data from this first randomized, placebo-controlled Phase 3 study of an amyloid targeting agent on top of standard of care chemotherapy. These post hoc analyses suggest that in the category of patients at highest risk for early mortality, NEOD001 has the potential to provide a survival benefit on top of standard of care. We are therefore exploring potential business development opportunities that could result in further clinical investigation of NEOD001."